title: The role of Budesonide-MMX in active ulcerative colitis.
abstract: Traditional corticosteroids represent a well-established and effective treatment for active ulcerative colitis (UC). However, the severity of their systemic side effects, led in recent years to look for new steroid molecules that could reduce them, maximizing the anti-inflammatory activity. Budesonide has been one of the most studied steroid compounds and it has been approved for the treatment of mild to moderate active Crohn's disease (CD). In order to extend the release until the distally located inflammation, budesonide has been coupled with a controlled delivery system, called Multi-Matrix system (MMX), already successfully tested with oral mesalazine for the treatment of distal UC. After in vitro and in vivo models, the efficacy of Budesonide-MMX has been investigated in active UC with a first small phase II study, and partially encouraging results. This article will review the evidences on the use of budesonide in inflammatory bowel diseases and will discuss the role of Budesonide-MMX in active UC nowadays.
authors: University of Bologna, Bologna, Italy.
authors: Paolo
authors: P
authors: Gionchetti
authors: Chiara
authors: C
authors: Praticò
authors: Fernando
authors: F
authors: Rizzello
authors: Andrea
authors: A
authors: Calafiore
authors: Nunzia
authors: N
authors: Capozzi
authors: Massimo
authors: M
authors: Campieri
authors: Carlo
authors: C
authors: Calabrese
mesh_terms: D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D019819:Budesonide / Q000008:administration & dosage* / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000188:drug therapy*; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D019819:Budesonide